• EROGMED - effective patient recruitment
  • Our Areas of Expertise
  • Site Management
  • Site Assessment
  • Site Efficiency
  • Rescue Strategies
• ERGOMED'S full service provision
  • Consultancy
  • Phase I/II a Unit
  • Central Laboratory
  • Project Management
  • Monitoring
  • Pharmacovigilance
  • Regulatory Affairs
  • Data Management & Biostatistics
  • Quality Assurance
• EROGMED partners with Biotech Venture Capital
  • Co-development strategies
  • Co-development financing
  • Co-development deals
• Company
  • Overview
  • Keys to Success
  • Management
    • Miroslav Reljanovic
    • Klemens Schuette
    • Scott Ferguson
  • Jobs
  • News
  • Events
• Contact
  • Locations
  • Contact us
  • Legal Information
•  

NEWS INDEX

Frankfurt / Dubai, October, 30, 2007.
ERGOMED locates regional headquarters at DuBiotech in Dubai.
[more]

Frankfurt, Germany, October, 22, 2007.
ERGOMED opens new facility in Russia. Dr Sergei Drapkin appointed as Managing Director of Russian office.
[more]

Cambridge, UK, September, 10, 2007.
CeNeS and ERGOMED Report Start of Recruitment for Phase II trial of CNS 5161 in cancer pain.
[more]

Frankfurt, Germany, April, 23, 2007.
ERGOMED initiate study preparations of a phase III 675 patient trial in grasspollen allergy in Europe.



Frankfurt, Germany, November, 30, 2006.
ERGOMED Completes Recruitment in 360-Patient Osteoarthritis Study Two Months of Schedule
-- 360-patient pivotal phase III trial conducted in 3 European countries--

Frankfurt, Germany, July, 13, 2006.
Ergomed signs co-development deal with CeNeS Pharmaceuticals plc Collaboration in Phase II trials of CNS5161 for neuropathic pain.
[more]